Relevance DX3 puro-beta6 Cell Line is a melanoma cell line endogenously expressing a range of integrins, but not beta 6. The use of DX3-puro/beta6 as a matched pair with the DX3-puro cell line is a useful tool for studying beta 6 function or specificity of agents that interfere with beta 6.
Production Details As described in Hausner et al. Cancer Research (2007) Vol 67, p7833-7840. The human melanoma cell line DX3 was infected with pBabe retroviruses encoding puromycin resistance or, in addition, cDNA for human integrin beta 6. Cells were selected in puromycin (1.25 ug/mL) followed by magnetic bead sorting, using 10D5 (mouse anti-avh6; Chemicon International), according to the manufacturer's instructions (Dynal; Invitrogen). When growing these lines the antibiotic does not have to be there all the time. The avb6 expression can drift so recipients must check by flow cytometery after they have been in continuous passage, at least once a month. Use the above magnetic beads to re-select when this happens.
Recommended Growing Conditions DMEM + 10%FCS/1.25ug/ml puromycin. Antibiotic is not necessary all the time.
Notes Useful model for studying the function and activity of beta 6 integrin when used as a matched pair with the parent DX3 line. DX3 cells endogenously express a variety of integrins, but not beta 6. These cell lines have been used to validate the activity and selectivity of AvB6 binding peptides.
Hausner et al. 2009. Cancer Res. 69(14):5843-50. PMID: 19549907.
Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.
Hausner et al. 2009. Mol Imaging. 8(2):111-21. PMID: 19397856.
Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.
Hausner et al. 2007. Cancer Res. 67(16):7833-40. PMID: 17699789.
Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.